Enterome to Participate at the FBR Healthcare Series Conference and the Guggenheim Securities Microbiome Day in New York

Apr 13, 2016, 09:00 ET from Enterome Bioscience SA

PARIS and BOSTON, April 13, 2016 /PRNewswire/ --

ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announces that Pierre Bélichard, its Chief Executive Officer, will participate at the following conferences:

  • FBR Healthcare Series: New Prescriptions: Innovation in the Treatment of Diseases and Infections, April 20, New York 

Dr Bélichard will participate in a panel entitled The Human Microbiome and Applications in Novel Therapeutics at 8:30 am EST.

  • Guggenheim Securities Microbiome Day, April 21, New York 

The conference will include members of the senior management team from leading microbiome companies, key opinion leaders and investors to discuss how the microbiome is being harnessed to develop novel therapies for a broad spectrum of medical conditions.

About Enterome  

Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.

Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.

Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel diseases; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.

The Company was established in 2012 in Paris, France to develop the discoveries made by the INRA metagenomic platform. The Company has raised a total of €17.5 million from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and two strategic investors (Shire & INRA transfer).

Additional information about Enterome is available through its website:  http://www.enterome.com  

Pierre Belichard, CEO

David Dible / Mark Swallow / Marine Perrier, Citigate Dewe Rogerson

SOURCE Enterome Bioscience SA